A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma

Purpose The therapeutic index of proteasome inhibitors may be improved through selective inhibition of a sub-component of the ubiquitin-proteasome system, such as the NEDD8-conjugation pathway. This multicenter, phase I, dose-escalation study assessed safety and the maximum tolerated dose (MTD), pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhatia, Shailender, Pavlick, Anna C., Boasberg, Peter, Thompson, John A., Mulligan, George, Pickard, Michael D., Faessel, Hélène, Dezube, Bruce J., Hamid, Omid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919369/
https://www.ncbi.nlm.nih.gov/pubmed/27056178
http://dx.doi.org/10.1007/s10637-016-0348-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919369/
https://www.ncbi.nlm.nih.gov/pubmed/27056178
http://dx.doi.org/10.1007/s10637-016-0348-5

Ejemplares similares